Defiance Daily Target 2X Short PLTR ETF

OPTIMI HEALTH CORP

HCW Biologics

Silexion Therapeutics

Vida Global

GCL Global

BiomX

MetaVia

Micware

MicroAlgo

PLTR

PLTZ

PLTG

PLTU

PLTW

PTIR

PLOO

PLTD

Top investor Danny Vena believes Palantir Technologies (NASDAQ:PLTR) is a buy due to its strong growth trajectory, with Q1 2026 showing 85% year-over-year revenue growth. Despite concerns over its premium valuation, Vena highlights a favorable PEG ratio of ~0.52, suggesting the stock is undervalued. Wall Street consensus rates PLTR as a Moderate Buy, with a 12-month price target indicating a potential 40% upside.

- Palantir Technologies is experiencing strong revenue and profit growth, with Q1 2026 showing 85% year-over-year sales growth of $1.63 billion.  
- Despite concerns over its valuation, investor Danny Vena suggests that the company's robust growth potential and a PEG ratio of around 0.52 indicate it is still a buy.  
- The consensus on Wall Street is a Moderate Buy, reflecting 13 Buys, 4 Holds, and 2 Sells, with a 12-month average price target suggesting a potential upside of nearly 40%.

Tip Ranks

Palantir Tech

Leverage Shares 2X Long PLTR Daily ETF

Direxion Daily PLTR Bull 2X Shares

Roundhill PLTR WeeklyPay ETF

GraniteShares 2x Long PLTR Daily ETF

Leverage Shares 2x Cpd Acclrtd PLTRMnETF

Defiance Leveraged Long +Income PLTR ETF

Direxion Daily PLTR Bear 1X Shares

'It's All About the Math,' Says Top Investor About Palantir Stock

Palantir reported record U.S. growth with government revenue reaching $687 million in Q1 2026, an 84% increase year-over-year, prompting a full-year growth guidance boost to 71%. However, the company faces challenges in Europe as Germany's intelligence agency chose ChapsVision's ArgonOS, limiting its market presence. Analysts express a mixed outlook, noting potential as an AI operating system standard but cautioning against high valuations and dependence on government contracts.

- Palantir’s U.S. government revenue reached $687 million in Q1 2026, marking an 84% year-over-year increase, prompting management to raise full-year growth guidance to 71%.  
- The company faced a setback in Europe as Germany's intelligence agency chose ChapsVision over Palantir, citing data sovereignty issues.  
- While analysts recognize Palantir's potential to become a standard in AI operating systems, concerns about high valuation, slow international growth, and dependence on government contracts persist.

Palantir posts record growth but faces European market loss

Palantir remains a high-variance AI infrastructure bet where narrative and execution will matter equally over the next decade.

Where could Palantir be in 10 years? The bull and bear cases.

XDAT

Convergence Investment Partners LLC reduced its stake in Palantir Technologies Inc. (NASDAQ:PLTR) by 89.9% in Q4, selling 15,525 shares and retaining 1,751 shares valued at $311,000. Other hedge funds also adjusted their holdings, with some increasing their stakes significantly. Insider trading activity included sales by Ryan D. Taylor and David A. Glazer, totaling over $5 million. Despite mixed sentiments, analysts remain optimistic about Palantir's growth potential in AI and government software.

- Convergence Investment Partners LLC reduced its stake in Palantir Technologies Inc. by 89.9% during the fourth quarter, holding 1,751 shares valued at $311,000 by the quarter's end.  
- Other hedge funds like Bare Financial Services and Clayton Financial Group increased their stakes, highlighting ongoing interest in Palantir despite recent insider selling.  
- Palantir's stock is currently rated as a Moderate Buy, with a consensus target price of $195.16 amidst mixed market sentiments and strong quarterly performance reporting.

Market Beat

Franklin Exponential Data ETF

iShares Expanded Tech Software Sector ETF

Proshares Big Data Refiners ETF

SPDR S&P Software

Ondas

Convergence Investment Partners LLC Sells 15,525 Shares of Palantir Technologies Inc. $PLTR

Palantir, a US technology firm, is facing criticism in the UK for its involvement in the NHS, with concerns over privacy and surveillance. Critics, including prominent figures and the British Medical Journal, argue that its data handling undermines NHS values. Despite this, Palantir claims to improve healthcare efficiency, with over 120 trusts using its platform. The debate centers on whether Palantir's technology is a solution to bureaucratic issues or a threat to civil liberties and trust in public institutions.

- Palantir, a US technology company, is facing criticism for its data handling and ties to military operations while also promising improvements to public services, particularly the NHS, where it has secured significant contracts.  
- Critics argue that its involvement undermines privacy and threatens the traditional patient-doctor relationship by centralizing health records, shifting control from GPs to the state.  
- Despite concerns, supporters highlight the efficiency gains from Palantir's technology, suggesting it could address longstanding bureaucratic challenges in the UK's health system.

The telegraph

Machiavellian spy firm or NHS saviour? The US giant love-bombing Britain

Palantir shares are down in 2026 after huge gains over the past three years.

NASDAQ Composite Index

This tech stock has outperformed the Nasdaq 3 years running, but is down 25% in 2026. Is now the time to buy?

Ukraine Will Leverage Palantir’s AI Capabilities In Its War With Russia. This Helps Prove PLTR Stock Will Never Be Irrelevant.

Barchart Option

Ukraine Will Leverage Palantir’s AI Capabilities In Its War With Russia. This Helps Prove PLTR Stock Will Never Be Irrelevant.

CLOU

Retail traders are trimming holdings of longtime AI favorite Palantir in a pivot from software stocks

businessinsider

Global X Cloud Computing ETF

ISHRS S&P Glb It

iShares US Digital Infrastructure and Real Estate ETF

Global X Data Center & Dgtl Infrs ETF

Retail traders are trimming holdings of longtime AI favorite Palantir in a pivot from software stocks

Palantir's stock has seen a pullback following earnings, yet its strong revenue growth and increasing analyst targets indicate that the bullish outlook remains valid. Despite this, Palantir is not among the top stock recommendations from leading analysts, who suggest other stocks may be better investment options at this time.

- MarketBeat highlights that Palantir Technologies has a Moderate Buy rating from analysts.  
- However, it notes that top-rated analysts recommend five other stocks as better investment options before the market recognizes their potential.  
- Investors considering Palantir Technologies should be aware of these alternative recommendations.

Palantir's Critics Are "Right"—But They're Also Still Wrong

The article discusses a bearish outlook on Palantir Technologies (NASDAQ:PLTR), despite strong Q1 2026 revenue growth of 85% year-over-year to $1.633 billion and a 133% increase in U.S. commercial revenue. The stock's high valuation metrics, including a trailing P/E of 155 and significant insider selling by executives, raise concerns about sustainability. The author expresses skepticism about the stock's current price, suggesting that while the company is strong, the stock is overvalued. They recommend considering other investment options with better risk/reward profiles.

- Palantir (PLTR) reported Q1 2026 revenue of $1.633 billion, an 85% increase year-over-year.  
- The company experienced a 133% growth in U.S. commercial revenue but has a trailing P/E ratio of 155 and a price-to-sales ratio of 62.  
- Notably, CEO Alex Karp and founder Peter Thiel have been actively selling shares since February 2026.

Defiance Daily Target 2X Short PLTR ETF(PLTZ.US)

'It's All About the Math,' Says Top Investor About Palantir Stock

Palantir posts record growth but faces European market loss

Where could Palantir be in 10 years? The bull and bear cases.

Convergence Investment Partners LLC Sells 15,525 Shares of Palantir Technologies Inc. $PLTR

Machiavellian spy firm or NHS saviour? The US giant love-bombing Britain